Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “c-MET Positive Gastric Cancer”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Study completedNCT02435108
What this trial is testing

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

Who this might be right for
c-MET Positive Gastric Cancer
Samsung Medical Center 2
Testing effectiveness (Phase 2)Study completedNCT01874938
What this trial is testing

LY2875358 in Participants With MET Positive, Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Eli Lilly and Company 15
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Large-scale testing (Phase 3)Ended earlyNCT01697072
What this trial is testing

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric Cancer
Amgen 609
Large-scale testing (Phase 3)Ended earlyNCT02137343
What this trial is testing

Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer

Who this might be right for
Gastric Cancer
Amgen 34
Large-scale testing (Phase 3)Study completedNCT01662869
What this trial is testing

Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 564